scholarly journals What do we Mean by “Ideal” Blood Pressure Control?

Kardiologiia ◽  
2021 ◽  
Vol 61 (7) ◽  
pp. 68-78
Author(s):  
O. D. Ostroumova ◽  
A. I. Kochetkov ◽  
N. A. Arablincky ◽  
N. A. Shatalova ◽  
R. R. Romanovsky ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Cognitive Disorders ◽  
Pressure Control ◽  
Fixed Dose ◽  
Cerebrovascular Complications ◽  
Dose Combination ◽  
Numerous Data ◽  
Cognitive Disorders And Dementia

Arterial hypertension (AH) is one of the most important risk factors for development of myocardial infarction, chronic heart failure, stroke, cognitive disorders and dementia, and chronic kidney disease. Currently, special attention is paid to increased blood pressure variability (BPV) as a new risk factor for development of cardiovascular and cerebrovascular complications. The available evidence-based body of clinical studies demonstrates the importance of reducing not only the blood pressure itself but also the increased BPV to provide significant improvement of the prognosis and limits the risk of complications. This notion has been validated in consensus documents on the management of patients with AH. Among antihypertensive drugs, the fixed-dose combination (FC) amlodipine/perindopril has demonstrated a unique capability for reducing all types of BPV (visit-to-visit, day-to-day, during 24 h). According to current clinical guidelines, this combination belongs to first-line FCs indicated for most patients with AH. A distinctive feature of the FC amlodipine/perindopril is numerous data from real-life clinical practice, which support both its high antihypertensive efficacy and the ability to decrease high BPV. Therefore, the FC amlodipine/perindopril can be recommended for a broad range of AH patients to achieve BP control and to improve the prognosis.

FIXED DOSE COMBINATION THERAPY IS ASSOCIATED WITH BETTER BLOOD PRESSURE CONTROL AND LOWER ALBUMINURIA IN REAL-LIFE COHORT DURING 7 YEARS OF FOLLOW UP. ENAH – CROATIAN RURAL STUDY

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e169
Author(s):  
A. Jelakovic ◽  
M. Abramovic ◽  
Z. Dika ◽  
V. Domislovic ◽  
K. Djapic ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Combination Therapy ◽  
Blood Pressure Control ◽  
Real Life ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Rural Study ◽  
Dose Combination

scholarly journals Achieving Blood Pressure Control with Telmisartan and Fixed Dose Combination of Telmisartan and Hydrochlorothiazide

2016 ◽  
Vol 11 (10-11) ◽  
pp. 598-601
Author(s):  
Anja Zaletel ◽  
Polona Knavs Vrhunec ◽  
Breda Barbič-Žagar
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

SCOPE AND NEED OF COMBINATION OF ANTIHYPERTENSIVE DRUGS

INDIAN DRUGS ◽  
2012 ◽  
Vol 49 (05) ◽  
pp. 5-19
Author(s):  
S. R Pattan ◽  
◽  
A. O. Zanwar ◽  
N. B Wabale ◽  
U. B. Shetkar
Keyword(s):  
Blood Pressure ◽  
Ace Inhibitors ◽  
Antihypertensive Drugs ◽  
Beta Blockers ◽  
Blood Pressure Reduction ◽  
Pressure Control ◽  
Channel Blockers ◽  
Once Daily ◽  
First Line Therapy ◽  
Dose Combination

The recommendation for first-line therapy for hypertension remains a beta blocker or diuretic given in a low dosage. A target blood pressure of less than 140/90 mm Hg is achieved in about 50 percent of patients treated with monotherapy; two or more agents from different pharmacological classes are often needed to achieve adequate blood pressure control. Single-dose combination antihypertension therapyis an important option that combines efficacy of blood pressure reduction and a low side effect profilewith convenient once-daily dosing to enhance compliance. Combination antihypertensives include combined agents from the following pharmacological classes: diuretics and potassium-sparing diuretics,beta blockers and diuretics, angiotensin-converting enzyme (ACE) inhibitors and diuretics, angiotensin-II antagonists and diuretics and calcium channel blockers and ACE inhibitors.

HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201

2010 ◽  
Vol 28 ◽  
pp. e108
Author(s):  
MA Prieto Diaz ◽  
JA Divison Garrote ◽  
J Abellan Aleman ◽  
JL Llisterri Caro ◽  
NR Robles P&;eacute;rez-Monteoliva ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Combination Treatments ◽  
Dose Combination

scholarly journals Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice

2017 ◽  
Vol 34 (4) ◽  
pp. 975-985 ◽  
Author(s):  
Alberto Mazza ◽  
Salvatore Lenti ◽  
Laura Schiavon ◽  
Antonella Paola Sacco ◽  
Fabio Dell’Avvocata ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Blood Pressure Control ◽  
Antihypertensive Drugs ◽  
Pressure Control ◽  
Fixed Dose ◽  
Triple Combination

scholarly journals Efficiency of monotherapy for blood pressure control: results of Ukrainian MAHNAT study

2019 ◽  
Vol 26 (5) ◽  
pp. 11-20
Author(s):  
L. А. Mishchenko
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Therapy ◽  
Urban Population ◽  
Demographic Data ◽  
Control Process ◽  
Pressure Control ◽  
Fixed Dose ◽  
Patient Profile ◽  
Ambulatory Patients ◽  
Dose Combination

The aim – to define a patient profile who underwent monotherapy, to study the therapy efficiency for blood pressure (BP) control and the prevalence rate of masked uncontrolled arterial hypertension (MUAH) among urban population in Ukraine and also to assess BP dynamics followed the correction of antihypertensive therapy. Materials and methods. 1837 arterial hypertensive patients from 12 regional centers of Ukraine and Kyiv, treated with monotherapy, were included in the multi focused study MAHNAT. At the initial visit demographic data, anamnesis, cardiovascular risk factors and results of physical examination were estimated. Home BP monitoring (HBPM) and ambulatory BP monitoring (ABPM) were performed against the background of monotherapy and before the last visit against the background of modified antihypertensive treatment. After assessing the results of office and ambulatory BP measurements during the second visit a physician identified the further tactic of antihypertensive therapy and prescribed the medicine. In the majority of cases, the doctors preferred dual combination therapy with the original fixed-dose combination (FDC) of perindopril/amlodipine. Its efficacy and tolerability were assessed on the 2nd and 4th week of treatment. Results and discussion. Effectiveness of monotherapy for the achievement of the target BP was 20.5 % according to office BP (BP < 140/90 mm Hg), 10.9 % – to HBPM (mean BP < 135/85 mm Hg) and 8.4 % – to ABPM (24-hour mean BP < 135/85 mm Hg). The efficient control process for target office BP was notified in 36.8 % patients and in 63.2 % ambulatory patients respectively. High normal BP (HR=1.54; 95 % CI 1.02–2.44; р=0.02), age over 55 (HR=0.39; 95 % CI 0.26–0.58; р<0.001) and diabetes mellitus (HR=2.44; 95 % CI 1.06–5.64; р=0.03) were the predictors of MUAH. Transfer to FDC perindopril/amlodipine resulted in decrease of systolic BP (SBP) by 15.6 % and diastolic BP (DBP) by 12 % after 4 weeks (p<0.001 for both parameters), which was accompanied with target office BP achievement at 92,8 % patients. The average home SBP/DBP declined by 15.1 %/11.3 % as well as average 24-hour SBP/DBP by 14.6 %/12.6 % (p<0.001 for both parameters). Treatment with FDC of perindopril/amlodipine promoted lowering the rate of MUAH from 63.2 to 27.5 %. Conclusions. The effectiveness of monotherapy in the achievement of target BP is 20.5 % among the urban population of Ukraine; according to out-of-office measurements – 10.6 % and 8.3 % by HBPM and ABPM respectively. Transfer from monotherapy to FDC perindopril/amlodipine allowed to improve office BP significantly and to lower the frequency of MUAH by 27.5 %.

scholarly journals Effect of a fixed-dose combination of perindopril arginine/amlodipine on the level and variability of blood pressure according to its office visit-to-visit measurements and self-measurements at home: A subanalysis of the PREVOSHODSTVO (SUPERIORITY) program

2017 ◽  
Vol 89 (8) ◽  
pp. 29-36
Author(s):  
O D Ostroumova
Keyword(s):  
Blood Pressure ◽  
Combination Therapy ◽  
Patient Group ◽  
Antihypertensive Drugs ◽  
Office Visit ◽  
Fixed Dose Combination ◽  
Uncontrolled Hypertension ◽  
Fixed Dose ◽  
Dose Combination

Aim. To study the effect of a fixed-dose combination of perindopril arginine/amlodipine (prestans) on the goal levels and variability of blood pressure (BP) according to its office visit-to-visit measurements and self-measurement (OVVM and SM) in a subgroup of 483 people from the population of the Russian observational SUPERIORITY program, most cases of whom are given the combination replacing the previously ineffective mono- and combination antihypertensive therapy (AHT). Subjects and methods. The subanalysis included data on 483 patients (34% men) aged 57.9±10.8 years with uncontrolled hypertension, who were both untreated and treated with antihypertensive mono- or combination therapy using a free or fixed-dose combination of 2—3 antihypertensive drugs and in whom the physicians decided to use prestans to correct AHT. The follow-up period was 24 weeks. Results. At the end of the investigation, the patients received prestans in the following doses: 5/5 mg (34% of the patients), 10/5 mg (39.5%), 5/10 mg (3.9%), and 10/10 mg (22%). In the analyzed patient group, the baseline BP was 160.8±8.8/92.6±7.4 mm Hg and dropped to 125.9±7.9/77.8±5.0 mm Hg at 24 weeks (p

Sign in / Sign up

Export Citation Format

Share Document